Bajaj Harpreet S, Goldenberg Ronald M
LMC Diabetes & Endocrinology, Brampton, Ontario, Canada.
LMC Diabetes & Endocrinology, Concord, Ontario, Canada.
touchREV Endocrinol. 2023 May;19(1):4-6. doi: 10.17925/EE.2023.19.1.4. Epub 2023 Mar 16.
Insulin icodec is a once-weekly basal insulin analogue in late-phase clinical development. Similar efficacy and safety of icodec to once-daily basal insulin analogues have been reported in over 4,200 participants with type 2 diabetes from three phase II and five phase III trials. Indeed, glycated haemoglobin reduction was superior for icodec among insulin-naïve participants (ONWARDS 1, 3 and 5) and in those switching from a daily basal insulin in ONWARDS 2, with the latter trial demonstrating improved diabetes treatment satisfaction scores with insulin icodec versus insulin degludec.
icodec胰岛素是一种处于临床后期开发阶段的每周一次基础胰岛素类似物。在来自三项II期和五项III期试验的4200多名2型糖尿病患者中,已报告icodec与每日一次基础胰岛素类似物具有相似的疗效和安全性。事实上,在初治胰岛素患者(ONWARDS 1、3和5)以及从每日基础胰岛素转换过来的患者(ONWARDS 2)中,icodec降低糖化血红蛋白的效果更佳,后一项试验表明,与德谷胰岛素相比,icodec胰岛素治疗糖尿病的满意度得分更高。